Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Ephrin Type B Receptor 4 Pipeline Drugs Market Report Overview
Ephrin type-B receptor 4 is a protein encoded by the EPHB4 gene. It binds promiscuously to transmembrane ephrin-B family ligands residing on adjacent cells which leads to contact dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. It plays a central role in heart morphogenesis and angiogenesis through the regulation of cell adhesion and cell migration. It plays an important role in postnatal blood vessel remodeling, morphogenesis, and permeability.
The Ephrin Type B Receptor 4 drugs in development market research report provides comprehensive information on the therapeutics under development for Ephrin Type B Receptor 4, complete with an analysis of products under development by stage of development, therapy area, and indication. It also provides market assessment by mechanisms of action (MoA), route of administration (RoA), and molecule type. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ephrin Type B Receptor 4 and features dormant and discontinued projects.
Ephrin Type B Receptor 4 Pipeline Drugs Market Segmentation by Therapy Area
The key therapy areas in the Ephrin Type B Receptor 4 pipeline drugs market are Oncology, Genetic Disorders, and Infectious Diseases. The majority of the pipeline drugs belong to oncology therapy.
Ephrin Type B Receptor 4 Pipeline Drugs Market Analysis, by Therapy Area
For more therapy area insights into the Ephrin Type B Receptor 4 pipeline drugs market, download a free report sample
Ephrin Type B Receptor 4 Pipeline Drugs Market Segmentation by Mechanisms of Action
The mechanism of action in the Ephrin Type B Receptor 4 pipeline drugs market is Ephrin Type B Receptor 4 Inhibitor.
For more MoA insights into the Ephrin Type B Receptor 4 pipeline drugs market, download a free report sample
Ephrin Type B Receptor 4 Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Ephrin Type B Receptor 4 pipeline drugs market are intravenous, intravesical, and oral. The majority of the pipeline drugs followed the intravenous route of administration.
Ephrin Type B Receptor 4 Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Ephrin Type B Receptor 4 pipeline drugs market, download a free report sample
Ephrin Type B Receptor 4 Pipeline Drugs Market Segmentation by Molecule Types
The leading molecule types in the Ephrin Type B Receptor 4 pipeline drugs market are small molecule, fusion protein, and synthetic peptide. Small molecule was the leading molecule type in the pipeline.
Ephrin Type B Receptor 4 Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Ephrin Type B Receptor 4 pipeline drugs market, download a free report sample
Ephrin Type B Receptor 4 Pipeline Drugs Market - Competitive Landscape
There are only two companies involved in the development of Ephrin Type B Receptor 4 Drugs in the market, which are Kadmon Holdings Inc and VasGene Therapeutics Inc. VasGene Therapeutics Inc was the leading one among them.
Ephrin Type B Receptor 4 Pipeline Drugs Market Analysis by Key Companies
To know more about the Ephrin Type B Receptor 4 pipeline drugs market companies, download a free report sample
Ephrin Type B Receptor 4 Pipeline Drugs Market Report Overview
Key Mechanism of Actions | Ephrin Type B Receptor 4 Inhibitor |
Key Therapy Areas | Oncology, Infectious Disease, and Genetic Disorders |
Key Routes of Administration | Intravenous, Intravesical, and Oral |
Key Molecule Types | Small Molecule, Fusion Protein, and Synthetic Peptide |
Key Companies | Kadmon Holdings Inc and VasGene Therapeutics Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape of Ephrin Type B Receptor 4
- The report reviews pipeline therapeutics for Ephrin Type B Receptor 4 by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Ephrin Type B Receptor 4 therapeutics and enlists all their major and minor projects
- The report assesses Ephrin Type B Receptor 4 therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news related to pipeline therapeutics for Ephrin Type B Receptor 4
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the Ephrin Type B Receptor 4 pipeline drugs market?
The key therapy areas in the Ephrin Type B Receptor 4 pipeline drugs market are oncology, genetic disorders, and infectious disease.
-
What is the key mechanism of action in the Ephrin Type B Receptor 4 pipeline drugs market?
The key mechanism of action in the Ephrin Type B Receptor 4 pipeline drugs market is Ephrin Type B Receptor 4 Inhibitor.
-
What are the key routes of administration in the Ephrin Type B Receptor 4 pipeline drugs market?
The key routes of administration in the Ephrin Type B Receptor 4 pipeline drugs market are intravenous, intravesical, and oral.
-
What are the key molecule types in the Ephrin Type B Receptor 4 pipeline drugs market?
The molecule types in the Ephrin Type B Receptor 4 pipeline drugs market are small molecule, fusion protein, and synthetic peptide.
-
Which are the key companies in the Ephrin Type B Receptor 4 pipeline drugs market?
The key companies in the Ephrin Type B Receptor 4 pipeline drugs market are Kadmon Holdings Inc and VasGene Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.